| 初诊急性髓系白血病骨髓CD34+CD38-细胞群比例是初次诱导缓解率的预后因素 |
| |
| 作者姓名： | Zhang CP Wei H Wang HJ Huai L He K Chen YR Lin D Wang JX |
| |
| 作者单位： | 中国医学科学院,北京协和医学院血液学研究所,血液病医院白血病诊疗中心,实验血液学国家重点实验室,天津300020 |
| |
| 基金项目： | 卫生行业科研专项,国家自然科学基金,天津市应用基础及前沿技术研究计划 |
| |
| 摘 要： | 为了研究非M3急性髓系白血病(AML non-M3) CD34+ CD38 -细胞群及其G0期比例与临床和实验室特征的关系,使用流式细胞仪检测40例初治AML non-M3骨髓单个核细胞CD34和CD38的表达,测定各群细胞的细胞周期,并分析CD34+ CD38 -细胞群及其G0期比例与临床实验室特征及初次诱导缓解率的关系.结果显示,CD34+ CD38 -细胞群及其G0期的比例与染色体核型、初诊WBC计数及FLT3/ITD阳性均无明显相关性,但与诱导治疗后骨髓中幼稚细胞比例相关.诱导停疗第7天骨髓中有幼稚细胞患者CD34+ CD38-细胞比例为(12.47±26.26)％,诱导停疗第7天无幼稚细胞患者CD34+ CD38 -细胞比例为(2.62±7.20)％ (p =0.031).诱导停疗第1天骨髓中可见幼稚细胞患者CD34+细胞群比例为(17.40±21.20)％,而诱导停疗第1天无幼稚细胞患者该比例为(5.64±6.96)％(p=0.00l).CR组患者治疗前CD34+ CD38 -细胞群的比例为(2.51±9.72)％,明显低于非CR组患者(24.92 +27.04％) (p =0.001).而在AMI non-M2b患者中,CR组患者治疗前CD34+ CD38 -细胞群的比例为(1.60±4.82)％,较非CR组患者更为降低(p ＜0.001).单因素分析显示,诱导化疗后是否取得CR与年龄(p=0.022)、CD34+ CD38 -细胞群比例(p=0.008)、诱导停疗第7天骨髓幼稚细胞比例(p=0.011)相关.多因素分析显示,仅有CD34+ CD38 -细胞群的比例与是否获得CR有相关趋势(p =0.052).结论:初治AML患者CD34+CD38 -细胞群的比例是AML初次诱导缓解率的预后因素.
|
| 关 键 词： | 急性髓系白血病 细胞周期 CD34+ CD38 - 缓解率 |
Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete rimission at first course of induction chemotherapy |
| |
| Zhang CP,Wei H,Wang HJ,Huai L,He K,Chen YR,Lin D,Wang JX.Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete rimission at first course of induction chemotherapy[J].Journal of Experimental Hematology,2011,19(5):1268-1272. |
| |
| Authors: | Zhang Cui-Ping Wei Hui Wang Hui-Jun Huai Lei He Kan Chen Yi-Rui Lin Dong Wang Jian-Xiang |
| |
| Institution: | ZHANG Cui-Ping,WEI Hui,WANG Hui-Jun,HUAI Lei,HE Kan,CHEN Yi-Rui,LIN Dong,WANG Jian-Xiang Leukemia Diagnosis and Treatment Center,State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Disease Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin 300020,China |
| |
| Abstract: | This study was to investigate the relationship between the CD34+CD38-cell population and its proportion in G0 phase of de novo AML non-M3 at diagnosis and the clinical and experimental characteristics.The flow cytometry was used to detect the expression of the cell surface antigen CD34 and CD38 in the bone marrow mononuclear cells(MNC) of the AML non-M3 at diagnosis and investigate the cell cycle of the subpopulations,and then the relationships between the proportion of CD34+CD38-cell population and its G0 ... |
| |
| Keywords: | acute myeloid leukemia cell cycle CD34 CD38- complete remission rate |
| 本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录！ |
|
